EMBOTAPE

*Each 28.5g syringe contains 11.4g pyrantel embonate/syringe*

**INDICATIONS**

Pyrantel Embonate is a broad spectrum anthelmintic. Pyrantel embonate is indicated for use in the horse for the control and treatment of adult infections of large and small strongyles, pinworms, roundworms and tapeworms.

**BENEFITS**

- For the treatment and control of adult infestations of large and small redworms ascarids and pinworms
- For the treatment and control of tapeworm
- Calibrated syringe for accurate dosage
- Broad spectrum activity of pyrantel embonate

**PACKAGING**

<table>
<thead>
<tr>
<th>LIST NO.</th>
<th>UNIT PACKAGE</th>
<th>CASE SIZE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1EMB004</td>
<td>28.5G SYRINGE</td>
<td>20</td>
</tr>
</tbody>
</table>

See reverse side for Administration and Dosage.
Pyrantel embonate 11.4g/syringe

**TARGET SPECIES**
Horses and ponies.

**INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES**
Pyrantel embonate is a broad spectrum anthelmintic. Pyrantel embonate is indicated for use in the horse for the control and treatment of adult infections of large and small strongyles, Pinworms, Roundworms, Tapeworms.

Pyrantel embonate has a broad spectrum of activity, including activity against:
- **TARGET SPECIES**
- Cyathostomes (Cyathostomum spp., Trichonema spp., Strongylus edentatus, Strongylus equinus)
- **Systemic nematodes**
- Strongyles (Parasarcis vivipara, Cyathostomum spp., Trichonema spp.)
- Pinworms (Oxyuris equi, Probstmayria vivipara)
- Tape worms: Anoplocephala perfoliata.

Pyrantel embonate is a broad spectrum anthelmintic belonging to another pharmacological class and having a different mode of action should suggest resistance to a particular anthelmintic, an appropriate test (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to pyrantel, and levamisole or piperazine is not recommended.

**AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE CONTROL AND TREATMENT OF STRONGYLES, OXYURIS AND PARASARCIS:**
Embotape should be used at a dose rate of 19 mg pyrantel embonate per kg bodyweight. The dosing programmes are as follows:
- a) Foals (1-8 months of age): dose every 4 weeks.
- b) Horses (over 8 months of age): dose every 6-8 weeks, but during the summer and autumn when at grass do every 4 weeks. Always dose 3-4 days before turning out after in wintering.
- c) Suckler mares: It has been shown that reduction of strongyle challenge to the suckling foal at pasture can be achieved by using clean pasture (re-seeded or not grazed the previous year by horses), dosing the mare 3-4 days before turning out and then at intervals of 2-4 weeks until the end of Autumn.
- Ideally mares with foals should go out to ‘clean’ pasture or, if this is not possible, delay turning them out until June.

The prescribed amount of Embotape is deposited on the tongue of the animal and the animal allowed to swallow. The complete content of one syringe contains 11.4g pyrantel embonate (6 graduated doses of 1.9g) in 28.5g paste and is sufficient for the treatment of 600kg bodyweight. Each graduation of the syringe is sufficient for the treatment of 100kg bodyweight.

**CONTROL AND TREATMENT OF ANOPLOCEPHALA (TAPEWORM):**
Embotape should be used at a dose rate of 38mg pyrantel embonate per kg bodyweight (i.e. twice the dose used for strongyles). The need for re-treatment may vary, but if considered necessary, should be carried out after an interval of 6 weeks. To ensure administration of a correct dose, body weight should be determined as accurately as possible, and accuracy of the dosing device should be checked.

Pyrantel embonate, at dosages of up to 60mg/kg bodyweight, as base, (some 20 times the standard therapeutic dose) had no adverse effects on horses, ponies or foals. Monitoring included haematological parameters, serum cholesterol and cholesterol and glutamic oxaloacetic transaminase levels.

**WITHDRAWAL PERIODS**
Not to be used in horses and ponies intended for human consumption. Treated horses may never be slaughtered for human consumption.

The horse must have been declared as not intended for human consumption under national veterinary medicines legislation.

**INCOMPATIBILITIES (MAJOR)**
None Known

**SHELF LIFE**
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

**SPECIAL PRECAUTIONS FOR STORAGE**
Do not store above 25°C. Protect from direct sunlight.

**NATURE AND COMPOSITION OF IMMEDIATE PACKAGING**
28.5g white, low density polyethylene syringe with a low density polyethylene cap. The syringe is fitted with a screw ring on a graduated plunger allowing adjustment of 1 to 6 doses of the product.

**SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED VETERINARY MEDICINAL PRODUCT OR WASTE MATERIALS DERIVED FROM THE USE OF SUCH PRODUCTS, IF APPROPRIATE**
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**MARKETING AUTHORISATION HOLDER**
Cross Vetpharm Group Ltd. Broomhill Road, Tallaght, Dublin 24. Ireland

**MARKETING AUTHORISATION NUMBER**
Vm 12597/4043

**LEGAL CATEGORY:**
POM-VPS

**PACKAGE QUANTITIES:**
Single Syringe

A full product SPC is available on request from Bimeda or alternatively can be found on the VMD website.